Pheochromocytoma: Clinical Experience From a Single Tertiary Care Center in India.
adrenal
catecholamines
clincal experience
hypertension
hypertensive crisis
india
pheochromocytoma
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
10
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Pheochromocytoma is a catecholamine-secreting tumor arising from adrenomedullary chromaffin cells that has a varied clinical presentation. Identification of this tumor, which has episodic symptoms, is a diagnostic challenge for clinicians. Diagnosis at an appropriate time is important because it is associated with significant morbidity and mortality. This study aims to mitigate the limited availability of data in our geographical area. To assess the clinical, biochemical, and radiological features and outcomes of patients diagnosed with pheochromocytoma at our center. This is a retrospective study. Patients diagnosed with pheochromocytoma during 2015-2023 were included in the study. Clinical, biochemical, and radiological data were collected at presentation, post-surgery, discharge, and until the last follow-up; data were retrieved from hospital records. Statistical analysis was done using IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. This study included 19 patients, of whom 10 (52.6%) were female. The most common clinical presentation was a hypertensive crisis in patients with pre-existing hypertension (63.1%), followed by headache (47.3%). The classical triad of headache, palpitation, and sweating was seen in only three patients (15.7%). The mean tumor size was 5.01±2.06 cm, with a range of 2.5 to 12 cm. All patients underwent adrenalectomy; six patients (31.5%) had perioperative complications, with post-operative hypotension being the most common at 21% (n = 4), followed by an acute coronary event during alpha blockade in one patient (0.05%) and an intra-operative hypertensive crisis in one patient (5%). A biochemical remission rate post-surgery was achieved in 17 (89.47%) patients. Hypertensive crisis in patients with pre-existing hypertension was the predominant presenting feature in most of our patients. Female predominance was noted (52.3%) compared to males. Perioperative complications were observed in 31.5% of patients, with post-operative hypotension being the most common complication.
Identifiants
pubmed: 37575861
doi: 10.7759/cureus.41671
pmc: PMC10412895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e41671Informations de copyright
Copyright © 2023, LU et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2002 Mar 20;287(11):1427-34
pubmed: 11903030
J Clin Oncol. 2013 May 1;31(13):1690-8
pubmed: 23509317
Gland Surg. 2020 Apr;9(2):362-371
pubmed: 32420260
Clin Chem. 2005 Apr;51(4):735-44
pubmed: 15718487
J Am Coll Surg. 2008 May;206(5):953-9; discussion 959-61
pubmed: 18471733
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304
Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102
pubmed: 17237836
J Endocr Soc. 2017 Jul 01;1(7):957-964
pubmed: 29264546
N Engl J Med. 2019 Aug 8;381(6):552-565
pubmed: 31390501
Ann Surg Oncol. 2020 May;27(5):1338-1347
pubmed: 32112213